利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.016 秒)

    STENT
    5.
    发明公开
    STENT 有权
    支架术

    公开(公告)号：EP1437157A4

    公开(公告)日：2009-02-11

    申请号：EP02785924

    申请日：2002-10-16

    申请人： KAWASUMI LAB INC ,  IKEUCHI KEN ,  MORI KOUJI ,  IWATA HIROO ,  MITSUDOU KAZUAKI

    发明人： IKEUCHI KEN ,  MORI KOUJI ,  IWATA HIROO ,  MITSUDOU KAZUAKI ,  NOMIYAMA HIROAKI ,  YOSHIKAWA YOSHIHARU ,  WATANABE MASATOSHI ,  YAMASHITA SHUZOU ,  MURAKAMI KAZUNORI

    IPC分类号： A61F2/915 ,  A61M29/02

    CPC分类号： A61F2/915 ,  A61F2/91 ,  A61F2002/91533 ,  A61F2002/91558 ,  A61F2002/91575

    摘要： A stent (1) having a generally tubular body formed of annular units with a plurality of cells and extendable in a radial direction from the inside thereof, wherein the annular units (4) are formed by vertically connecting the plurality of cells (6) and a plurality of the connected cells are arranged so as to surround the center axis (C1) of the stent forming the tubular body, the annular unit is arranged in the axial direction of the stent, the annular units are connected to each other at least at one position through a connection part (5), the connection part is formed of a curved part (8) having two or more arcs and a generally straight part (7) continued to the curved part, the cells are arranged by three to eight units per 10 mm in length of the stent, and the ratio of the axial length (5L) of the connection part in stent axial direction to that (6L) of the cells in stent axial direction is set to 100 to 50 to 100, whereby a high flexibility and a radiation support force can be sufficiently assured and a vasodilating capability can be increased to suppress a fore-shortening and a flare event.

    摘要翻译： 1。一种支架（1），其具有大致管状的主体，该主体由具有多个单元的环状单元构成，并且能够从内侧沿径向延伸，其特征在于，所述环状单元（4）通过将多个单元（6） 多个连接单元以围绕形成管状体的支架的中心轴线（C1）的方式配置，环状单元沿支架的轴向配置，环状单元至少在 通过连接部分（5）的一个位置，连接部分由具有两个或更多个弧形的弯曲部分（8）和与弯曲部分连续的大致笔直部分（7）形成，单元以三至八个单元 每10mm长度的支架，并且连接部分在支架轴向上的轴向长度（5L）与支架轴向上的单元的轴向长度（6L）之比设定为100至50至100，由此a 高度的灵活性和辐射支撑力可以是足够的 非常有效地保证并且可以增加血管扩张能力来抑制缩短和眩光事件。

    METHOD OF PRODUCING NERVE CELL
    6.
    发明公开
    METHOD OF PRODUCING NERVE CELL 审中-公开
    一种用于生产神经细胞

    公开(公告)号：EP1783208A4

    公开(公告)日：2007-11-14

    申请号：EP05757788

    申请日：2005-07-06

    申请人： KYOWA HAKKO KOGYO KK ,  IWATA HIROO ,  SASAI YOSHIKI

    发明人： IWATA HIROO ,  SASAI YOSHIKI ,  YAMAZOE HIRONORI ,  KOBORI MASATO ,  SATOH MITSUO ,  YANO KEIICHI

    IPC分类号： C12N5/0793

    CPC分类号： C12N5/0619 ,  C12N2500/38 ,  C12N2506/02

    摘要： It is intended to provide: a method of producing nerve cells by inducing the differentiation of embryonic stem cells; a method of inducing the differentiation of embryonic stem cells into nerve cells; a medium to be used in the production method or the differentiation induction method as described above; or a method of elevating the purity of nerve cells obtained by inducing the differentiation of embryonic stem cells. Namely, a method of conveniently, selectively or economically producing nerve cells, which are applicable to the treatment of neurodegenerative diseases and the like, by inducing the differentiation of embryonic stem cells with the use of vitamin B12 or a salt thereof, and heparin, a substance having a heparin-like function or a salt thereof.

    Sustained drug-releasing stent
    8.
    发明公开
    Sustained drug-releasing stent 审中-公开
    支架zur stetigen Arzneimittelabgabe

    公开(公告)号：EP2258414A2

    公开(公告)日：2010-12-08

    申请号：EP10164082.9

    申请日：2008-09-03

    申请人： Japan Stent Technology Co., Ltd. ,  TOKAI UNIVERSITY EDUCATIONAL SYSTEM ,  Toyo Advanced Technologies Co., Ltd. ,  Iwata, Hiroo

    发明人： Iwata, Hiroo ,  Omura, Ikuo ,  Jin, Zhen Yu ,  Yamashita, Shuzo ,  Mochizuki, Akira

    IPC分类号： A61L31/10 ,  A61L31/16

    CPC分类号： A61F2/82 ,  A61F2/91 ,  A61F2/915 ,  A61F2002/91541 ,  A61F2250/0067 ,  A61K9/0024 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/416 ,  A61L2300/608 ,  A61L2420/08

    摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8 : 2 to 3 : 7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80 % by weight of the polymer being less than 20 % by weight.

    摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架主体，至少涂覆外表面的第一涂层和基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 为8：2至3：7.另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，药物的重量组成比为聚合物的80重量％ 小于20重量％。